摘要
目的评估复方甘草酸注射液(SNMC)治疗晚期妊娠乙型肝炎患者及新生儿的疗效、安全性及对新生儿接种乙型肝炎疫苗(HBVac)、乙型肝炎免疫球蛋白(HBIG)联合免疫应答的影响。方法收集100例医院妊娠晚期合并慢性乙型肝炎患者,随机分为复方甘草酸注射液治疗组(试验组)和腺苷蛋氨酸注射液治疗组(对照组),4周为1疗程,定期检测谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil);两组孕妇新生儿出生时测量体重、身长,计算Apgar评分,新生儿出生后12h、1、6个月分别给予HBVac 20、10、10μg肌内注射,同时于出生后12h及1个月肌内注射HBIG 200IU;1周岁时检测乙型肝炎表面抗体(抗-HBs)滴度以评估对新生儿联合免疫的影响。结果两组孕妇年龄、孕周及新生儿体重、身长、Apgar评分,相比较差异均无统计学意义;ALT的复常率,试验组优于对照组,分别为82.0%和60.0%(P<0.05);AST的复常率,试验组亦优于对照组,分别为88.0%和68.0%(P<0.05);两组治疗前后TBil的水平差异均无统计学意义;试验组与对照组1周岁婴儿抗-HBs阳性率分别为92.0%和94.0%,差异无统计学意义;试验组与对照组平均抗-HBs滴度为(553.9±72.35)mIU/ml和(537.6±53.54)mIU/ml,两组差异无统计学意义;两组新生儿联合免疫效果相仿。结论复方甘草酸注射液能改善患慢性乙型肝炎的晚期妊娠患者的肝功能,且不影响新生儿联合免疫。
OBJECTIVE To evaluate the efficacy and safety of stronger neo-minophagen C injection in treatment of chronic hepatitis B（CHB） patients with pregnancy and the newborns and its effect on immune response of hepatitis B vaccine（HBVac） and hepatitis B immune globulin（HBIG） in the newborns. METHODS A total of 100 chronic hepatitis B patients with in late pregnancy were collected and randomly divided into two groups： the group A and the group B. The cases in group A were treated with stronger neo-minophagen C injection （the experimental group） ,while the cases in group B were treated with ademetionine injection（the control group）. A course of treatment was four weeks, and the alanine aminatransferase （ALT）, aspartate aminotransferase（AST）, and total bilirubin（Tbil） were tested regularly. The neonatal weight and length were measured, and the Apgar score was calculated . HBVac 20ug,10ug,10ug were injected into the neonatal hips anterolateral muscle after the birth of 12 hours, a month and six months correspondently, while the HBIG 200 IU were respectively injected into the neonatal hips anterolateral muscle after the birth of 12 hours and a month. At the age of one, the influence of combined immunization in the newborns were assessed by hepatitis B surface antibody assay. RESULTS There was no statistical difference in the maternal age, gestational weeks, and the neonatal weight, length or apgar score between the two groups. The nomalization of ALT was 82.0% in the experimental group versus 60.0% in the control group（P=0,027）, the experimental group was better than the control group,and so was the nomalization of AST（88.0% vs 68.0% ,P=0. 028）. The difference in the pre-treatment level of TBil between the two groups was not statistically significant, and so was the level of TBil after the treatment. The positive rate of the hepatitis B surface antibody （HBsAb） was 92.0% of the group A and 94.0% of the group B, the difference was not statically significant. The average anti-HBs titer was （553.9±72.35）mIU/ml in the group A and（537. 6±53.54）mIU/ml in the group B, the difference was not statistically significant; the combined immunization of the newborns in the two groups was similar. CONCLUSION The stronger neo-minophagen C injection can improve the liver function of the chronic hepatitis B patients with late pregnancy , without the combined immunization of the newborns being affected.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2013年第6期1392-1394,共3页
Chinese Journal of Nosocomiology
关键词
慢性乙型肝炎
新生儿
联合免疫
肝功能
复方甘草酸
腺苷蛋氨酸
Chronic hepatitis B
Newborn
Combined immunization
Liver function
Stronger neo-minophagen C
Ademetionine
